These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

126 related articles for article (PubMed ID: 37226898)

  • 21. Platinum plus bortezomib for the treatment of pediatric renal medullary carcinoma: Two cases.
    Carden MA; Smith S; Meany H; Yin H; Alazraki A; Rapkin LB
    Pediatr Blood Cancer; 2017 Jul; 64(7):. PubMed ID: 28052556
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Therapeutic approach guided by genetic alteration: use of MTOR inhibitor in renal medullary carcinoma with loss of PTEN expression.
    Lipkin JS; Rizvi SM; Gatalica Z; Sarwani NE; Holder SL; Kaag M; Drabick JJ; Joshi M
    Cancer Biol Ther; 2015; 16(1):28-33. PubMed ID: 25692619
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Renal medullary carcinoma: molecular, pathological and clinical evidence for treatment with topoisomerase-inhibiting therapy.
    Schaeffer EM; Guzzo TJ; Furge KA; Netto G; Westphal M; Dykema K; Yang X; Zhou M; Teh BT; Pavlovich CP
    BJU Int; 2010 Jul; 106(1):62-5. PubMed ID: 20002663
    [TBL] [Abstract][Full Text] [Related]  

  • 24. The Anti-Tumor Activity of the NEDD8 Inhibitor Pevonedistat in Neuroblastoma.
    Foster JH; Barbieri E; Zhang L; Scorsone KA; Moreno-Smith M; Zage P; Horton TM
    Int J Mol Sci; 2021 Jun; 22(12):. PubMed ID: 34207315
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Marked anti-tumour activity of the combination of YM155, a novel survivin suppressant, and platinum-based drugs.
    Iwasa T; Okamoto I; Takezawa K; Yamanaka K; Nakahara T; Kita A; Koutoku H; Sasamata M; Hatashita E; Yamada Y; Kuwata K; Fukuoka M; Nakagawa K
    Br J Cancer; 2010 Jun; 103(1):36-42. PubMed ID: 20517311
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Triple combination of bevacizumab, gemcitabine and platinum salt in metastatic collecting duct carcinoma.
    Pécuchet N; Bigot F; Gachet J; Massard C; Albiges L; Teghom C; Allory Y; Méjean A; Escudier B; Oudard S
    Ann Oncol; 2013 Dec; 24(12):2963-7. PubMed ID: 24190963
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Renal Medullary Carcinoma: Establishing Standards in Practice.
    Beckermann KE; Sharma D; Chaturvedi S; Msaouel P; Abboud MR; Allory Y; Bourdeaut F; Calderaro J; de Cubas AA; Derebail VK; Hong AL; Naik RP; Malouf GG; Mullen EA; Reuter VE; Roberts CWM; Walker CL; Wood CG; DeBaun MR; Van Poppel H; Tannir NM; Rathmell WK
    J Oncol Pract; 2017 Jul; 13(7):414-421. PubMed ID: 28697319
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Renal cell carcinoma, unclassified with medullary phenotype: poorly differentiated adenocarcinomas overlapping with renal medullary carcinoma.
    Sirohi D; Smith SC; Ohe C; Colombo P; Divatia M; Dragoescu E; Rao P; Hirsch MS; Chen YB; Mehra R; Amin MB
    Hum Pathol; 2017 Sep; 67():134-145. PubMed ID: 28716439
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Targeting NEDDylation is a Novel Strategy to Attenuate Cisplatin-induced Nephrotoxicity.
    Jones TM; Espitia CM; Chipollini J; Lee BR; Wertheim JA; Carew JS; Nawrocki ST
    Cancer Res Commun; 2023 Feb; 3(2):245-257. PubMed ID: 36860653
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Overcoming platinum resistance in ovarian cancer by targeting pregnancy-associated plasma protein-A.
    Torres D; Hou X; Bale L; Heinzen EP; Maurer MJ; Zanfagnin V; Oberg AL; Conover C; Weroha SJ
    PLoS One; 2019; 14(11):e0224564. PubMed ID: 31751381
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Inactivation of the CRL4-CDT2-SET8/p21 ubiquitylation and degradation axis underlies the therapeutic efficacy of pevonedistat in melanoma.
    Benamar M; Guessous F; Du K; Corbett P; Obeid J; Gioeli D; Slingluff CL; Abbas T
    EBioMedicine; 2016 Aug; 10():85-100. PubMed ID: 27333051
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Excision repair cross-complementation group 1 (ERCC1) in platinum-based treatment of non-small cell lung cancer with special emphasis on carboplatin: a review of current literature.
    Vilmar A; Sørensen JB
    Lung Cancer; 2009 May; 64(2):131-9. PubMed ID: 18804893
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Genomic Characterization of Renal Medullary Carcinoma and Treatment Outcomes.
    Carlo MI; Chaim J; Patil S; Kemel Y; Schram AM; Woo K; Coskey D; Nanjangud GJ; Voss MH; Feldman DR; Hsieh JJ; Hakimi AA; Chen YB; Motzer RJ; Lee CH
    Clin Genitourin Cancer; 2017 Dec; 15(6):e987-e994. PubMed ID: 28558987
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Renal Medullary Carcinoma: A Surveillance, Epidemiology, and End Results (SEER) Analysis.
    Haupt T; Akinyemi O; Raju RA; Wadley AE; Nnorom S; Aponte V; Thelus J; Tonkin JB; Coleman PW; Metwalli AR
    J Surg Res; 2023 Dec; 292():1-6. PubMed ID: 37567029
    [TBL] [Abstract][Full Text] [Related]  

  • 35. SMARCB1/INI1 inactivation in renal medullary carcinoma.
    Calderaro J; Moroch J; Pierron G; Pedeutour F; Grison C; Maillé P; Soyeux P; de la Taille A; Couturier J; Vieillefond A; Rousselet MC; Delattre O; Allory Y
    Histopathology; 2012 Sep; 61(3):428-35. PubMed ID: 22686875
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Management and outcomes of patients with renal medullary carcinoma: a multicentre collaborative study.
    Shah AY; Karam JA; Malouf GG; Rao P; Lim ZD; Jonasch E; Xiao L; Gao J; Vaishampayan UN; Heng DY; Plimack ER; Guancial EA; Fung C; Lowas SR; Tamboli P; Sircar K; Matin SF; Kimryn Rathmell W; Wood CG; Tannir NM
    BJU Int; 2017 Dec; 120(6):782-792. PubMed ID: 27860149
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Population pharmacokinetics of pevonedistat alone or in combination with standard of care in patients with solid tumours or haematological malignancies.
    Faessel HM; Mould DR; Zhou X; Faller DV; Sedarati F; Venkatakrishnan K
    Br J Clin Pharmacol; 2019 Nov; 85(11):2568-2579. PubMed ID: 31355467
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Optimal chemotherapy treatment for women with recurrent ovarian cancer.
    Fung-Kee-Fung M; Oliver T; Elit L; Oza A; Hirte HW; Bryson P
    Curr Oncol; 2007 Oct; 14(5):195-208. PubMed ID: 17938703
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Prospective multicenter phase II study of gemcitabine plus platinum salt for metastatic collecting duct carcinoma: results of a GETUG (Groupe d'Etudes des Tumeurs Uro-Génitales) study.
    Oudard S; Banu E; Vieillefond A; Fournier L; Priou F; Medioni J; Banu A; Duclos B; Rolland F; Escudier B; Arakelyan N; Culine S;
    J Urol; 2007 May; 177(5):1698-702. PubMed ID: 17437788
    [TBL] [Abstract][Full Text] [Related]  

  • 40. SMARCB1 regulates a TFCP2L1-MYC transcriptional switch promoting renal medullary carcinoma transformation and ferroptosis resistance.
    Vokshi BH; Davidson G; Tawanaie Pour Sedehi N; Helleux A; Rippinger M; Haller AR; Gantzer J; Thouvenin J; Baltzinger P; Bouarich R; Manriquez V; Zaidi S; Rao P; Msaouel P; Su X; Lang H; Tricard T; Lindner V; Surdez D; Kurtz JE; Bourdeaut F; Tannir NM; Davidson I; Malouf GG
    Nat Commun; 2023 May; 14(1):3034. PubMed ID: 37236926
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.